Holen Sie sich die Stockscreener-App
2.405
2.24%
-0.055
Schlusskurs vom Vortag:
$2.46
Offen:
$2.47
24-Stunden-Volumen:
544.85K
Relative Volume:
0.48
Marktkapitalisierung:
$260.54M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-4.625
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+3.66%
1M Leistung:
+19.65%
6M Leistung:
+78.15%
1J Leistung:
-39.27%
1-Tages-Spanne:
$2.39
$2.57
1-Wochen-Bereich:
$2.2501
$2.6064
52-Wochen-Spanne:
$1.05
$4.55
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Vergleichen Sie ACRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.405 | 266.53M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.18 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
740.98 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.61 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.34 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
200.28 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-05-28 | Eingeleitet | Wedbush | Outperform |
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks - simplywall.st
How Aclaris Therapeutics Inc. stock benefits from tech adoptionNew Guidance & Smart Money Movement Alerts - newser.com
What hedge fund moves indicate for Aclaris Therapeutics Inc. (8AT) stockTrade Signal Summary & Daily Momentum Trading Reports - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock attracts HNW investors2025 Volatility Report & Verified Entry Point Detection - newser.com
Is Aclaris Therapeutics Inc. stock a contrarian buyPortfolio Performance Report & Entry Point Confirmation Signals - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock is a must watch ticker2025 Key Highlights & High Return Stock Watch Alerts - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock benefit from mergers2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock a buy for dividend portfoliosLayoff News & Fast Momentum Entry Tips - newser.com
How cyclical is Aclaris Therapeutics Inc. (8AT) stock compared to rivalsPortfolio Value Report & Daily Technical Stock Forecast Reports - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock bottoming after sell offJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com
Can Aclaris Therapeutics Inc. stock deliver strong Q4 earnings2025 Market Sentiment & Weekly Watchlist for Hot Stocks - newser.com
What high frequency data says about Aclaris Therapeutics Inc.2025 Market Outlook & Safe Entry Momentum Stock Tips - newser.com
Aclaris Therapeutics at Jefferies Conference: Strategic Expansion in Biopharma By Investing.com - Investing.com Canada
Will Aclaris Therapeutics Inc. stock deliver shareholder value2025 Dividend Review & Weekly Setup with ROI Potential - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock gets analyst attention2025 Short Interest & Risk Adjusted Swing Trade Ideas - newser.com
Is Aclaris Therapeutics Inc. stock trading at a premium valuationWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Will Aclaris Therapeutics Inc. benefit from macro trendsEarnings Summary Report & Community Trade Idea Sharing - newser.com
Key resistance and support levels for Aclaris Therapeutics Inc.2025 Trading Volume Trends & Fast Moving Trade Plans - newser.com
How Aclaris Therapeutics Inc. stock trades before earningsAnalyst Upgrade & Weekly Return Optimization Plans - newser.com
Statistical indicators supporting Aclaris Therapeutics Inc.’s strengthEarnings Growth Summary & Expert Curated Trade Setup Alerts - newser.com
Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 - MSN
Risk adjusted return profile for Aclaris Therapeutics Inc. analyzedJuly 2025 Levels & Verified Swing Trading Watchlist - newser.com
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):